Tags:BioTechCareLifeProduct
Atox Bio is a late-stage biotechnology company that develops immunotherapies for critically ill patients. Atox Bio's lead product, reltecimod, is being developed to treat necrotising soft tissue infection (NSTI) more commonly known as ‘flesh eating bacteria’, for which no current therapy exists. Reltecimod, is a novel peptide that modulates the body’s severe acute immune response and lowers morbidities and mortality. NSTI’s are rapidly progressing infections that result in significant tissue destruction and systemic disease leading to multiple organ dysfunction, failure and death.

Investors 1

Mentions in press and media 3

DateTitleDescriptionCategoryAuthorSource
04.12.2017Atox Bio C...Atox Bio, a Ness Ziona, Israel...Israel US...-finsmes.co...
25.07.2014Atox Bio R...Atox Bio, a Ness Ziona, Israel...Israel-finsmes.co...
19.12.2011Atox Bio R...Atox Bio, a Ness Ziona, Israel...funding I...-finsmes.co...